Recessive Osteogenesis Imperfecta Due to Mutations in CRTAP , LEPRE1 and PPIB - Osteogenesis Imperfecta - page 135

[19] Andrade MA, Perez-Iratxeta C, Ponting CP. Protein repeats: struc-

tures, functions, and evolution. J Struct Biol 2001;134(2-3):117-31.

intravenous pamidronate in children and adolescents with
osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111
(5 Pt 1):1030-6. [20] Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases,

a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci
1999;55(3):423-36.

[41] Cheung MS, Glorieux FH, Rauch F. Intravenous pamidro-

nate in osteogenesis imperfecta type VII. Calcif Tissue Int
2009;84(3):203-9. [21] Yao Q, Li M, Yang H, Chai H, Fisher W, Chen C. Roles of

cyclophilins in cancers and other organ systems. World J Surg
2005;29(3):276-80.

[42] Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S,

et al. Prolyl 3-hydroxylase 1 deiciency causes a recessive meta-
bolic bone disorder resembling lethal / severe osteogenesis imper-
fecta. Nat Genet 2007;39(3):359-65.

[22] Pemberton TJ, Kay JE. Identiication and comparative analysis

of the peptidyl-prolyl cis / trans isomerase repertoires of H. sapi-
ens, D. melanogaster, C. elegans, S. cerevisiae and Sz. pombe.
Comp Funct Genomics 2005;6(5-6):277-300.

[43] Willaert A, Malfait F, Symoens S, Gevaert K, Kayserili H,

Megarbane A, et al. Recessive osteogenesis imperfecta caused
by LEPRE1 mutations: clinical documentation and identiication
of the splice form responsible for prolyl 3-hydroxylation. J Med
Genet 2009;46(4):233-41.

[23] Sillence DO, Rimoin DL. Classiication of osteogenesis imper-

fect. Lancet 1978;1(8072):1041-2.

[24] Sillence DO. Osteogenesis imperfecta nosology and genetics.

Ann N Y Acad Sci 1988;543:1-15. [44] Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1

and CRTAP cause severe recessive osteogenesis imperfecta. Cell
Tissue Res 2010;339(1):59-70.

[25] Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC.

Perinatal lethal osteogenesis imperfecta (OI type II): a biochemi-
cally heterogeneous disorder usually due to new mutations in the
genes for type I collagen. Am J Hum Genet 1988;42(2):237-48.

[45] van Dijk FS, Nikkels PG, den Hollander NS, Nesbitt IM, van

Rijn RR, Cobben JM, et al. Lethal / severe osteogenesis imperfecta
in a large family: a novel homozygous LEPRE1 mutation and
bone histological indings. Pediatr Dev Pathol 2011;14(3):228-34.

[26] Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteo-

genesis imperfecta. J Med Genet 1979;16(2):101-16.

[27] Sillence DO, Barlow KK, Garber AP, Hall JG, Rimoin DL.

Osteogenesis imperfecta type II delineation of the phenotype
with reference to genetic heterogeneity. Am J Med Genet 1984;
17(2):407-23.

[46] Zhang ZL, Zhang H, Ke YH, Yue H, Xiao WJ, Yu JB, et al. The

identiication of novel mutations in COL1A1, COL1A2, and
LEPRE1 genes in Chinese patients with osteogenesis imperfecta.
J Bone Miner Metab 2012;30(1):69-77.

[28] Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P,

et al. Type V osteogenesis imperfecta: a new form of brittle bone
disease. J Bone Miner Res 2000;15(9):1650-8.

[47] Cabral WA, Barnes AM, Adeyemo A, Cushing K, Chitayat D,

Porter FD, et al. A founder mutation in LEPRE1 carried by 1.5%
of West Africans and 0.4% of African Americans causes lethal
recessive osteogenesis imperfecta. Genet Med 2012;14(5):543-51. [29] Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R.

Osteogenesis imperfecta type VI: a form of brittle bone disease
with a mineralization defect. J Bone Miner Res 2002;17(1):30-8.

[48] Takagi M, Ishii T, Barnes AM, Weis M, Amano N, Tanaka M,

et al. A novel mutation in LEPRE1 that eliminates only the
KDEL ER - retrieval sequence causes non-lethal osteogenesis
imperfecta. PloS One 2012;7(5):e36809.

[30] Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L,

et al. Osteogenesis imperfecta type VII: an autosomal recessive
form of brittle bone disease. Bone 2002;31(1):12-18. [49] White SD, Bourdeau P. Prevalence of the mutation in cyclophilin B

(PPIB), a causal candidate gene for HERDA, among Quarter Horses
in France. Vet Dermatol 2011;22(2):206-8.

[31] Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, Roughley PJ,

et al. Osteogenesis imperfecta type VII maps to the short arm of
chromosome 3. Bone 2002;31(1):19-25. [50] Tryon RC, White SD, Bannasch DL. Homozygosity mapping

approach identiies a missense mutation in equine cyclophilin B
(PPIB) associated with HERDA in the American Quarter Horse.
Genomics 2007;90(1):93-102.

[32] Tonachini L, Morello R, Monticone M, Skaug J, Scherer SW,

Cancedda R, et al. cDNA cloning, characterization and chromo-
some mapping of the gene encoding human cartilage associated
protein (CRTAP). Cytogenet Cell Genet 1999;87(3-4):191-4. [51] Barnes AM, Carter EM, Cabral WA, Weis M, Chang W,

Makareeva E, et al. Lack of cyclophilin B in osteogen-
esis imperfecta with normal collagen folding. N Eng J Med
2010;362(6):521-8.

[33] Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR,

et al. Deiciency of cartilage-associated protein in recessive lethal
osteogenesis imperfecta. N Eng J Med 2006;355(26):2757-64.

[34] Baldridge D, Schwarze U, Morello R, Lennington J, Bertin TK,

Pace JM, et al. CRTAP and LEPRE1 mutations in recessive osteo-
genesis imperfecta. Human Mutation 2008;29(12):1435-42.

[52] Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz DF,

Dineen R, et al. Mutations in PPIB (cyclophilin B) delay type I
procollagen chain association and result in perinatal lethal to
moderate osteogenesis imperfecta phenotypes. Hum Mol Genet
2011;20(8):1595-609.

[35] Bodian DL, Chan TF, Poon A, Schwarze U, Yang K, Byers PH,

et al. Mutation and polymorphism spectrum in osteogenesis
imperfecta type II: implications for genotype-phenotype rela-
tionships. Hum Mol Genet 2009;18(3):463-71.

[53] Vranka JA, Pokidysheva E, Hayashi L, Zientek K, Mizuno K,

Ishikawa Y, et al. Prolyl 3-hydroxylase 1 null mice display
abnormalities in ibrillar collagen-rich tissues such as tendons,
skin and bones. J Biol Chem 2010;285(22):17253-62.

[36] Van Dijk FS, Nesbitt IM, Nikkels PG, Dalton A, Bongers EM, van

de Kamp JM, et al. CRTAP mutations in lethal and severe osteo-
genesis imperfecta: the importance of combining biochemical and
molecular genetic analysis. Eur J Hum Genet 2009;17(12):1560-9.

[54] Garrone R. The collagen of the Porifera Bairati A, Garrone R,

editors. Biology of invertebrate and lower vertebrate collagens.
New York: Plenum Press; 1985. p. 157-75. [37] Valli M, Barnes AM, Gallanti A, Cabral WA, Viglio S, Weis M, et al.

Deiciency of CRTAP in non-lethal recessive osteogenesis imperfecta
reduces collagen deposition into matrix. Clin Genet 2012;82(5):453-9.

[55] Zhang X, Boot-Handford RP, Huxley-Jones J, Forse LN, Mould

AP, Robertson DL, et al. The collagens of hydra provide insight
into the evolution of metazoan extracellular matrices. J Biol
Chem 2007;282(9):6792-802.

[38] Morello R, Rauch F. Role of cartilage-associated protein in skel-

etal development. Curr Osteoporos Rep 2010;8(2):77-83.

[39] Obafemi AA, Bulas DI, Troendle J, Marini JC. Popcorn calcii-

cation in osteogenesis imperfecta: incidence, progression, and
molecular correlation. Am J Med Genet 2008;146A(21):2725-32.

[56] Exposito JY, Larroux C, Cluzel C, Valcourt U, Lethias C,

Degnan BM. Demosponge and sea anemone ibrillar collagen
diversity reveals the early emergence of A / C clades and the
maintenance of the modular structure of type V / XI collagens
from sponge to human. J Biol Chem 2008;283(42):28226-35.

[40] Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight

development during four years of therapy with cyclical